NASDAQ: PRTC - PureTech Health plc

Altı ay boyunca karlılık: -14.52%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı PureTech Health plc


Şirket hakkında PureTech Health plc

PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies.

daha fazla ayrıntı
It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

IPO date 2020-11-16
ISIN US7462371060
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.puretechhealth.com
Цена ао 16.75
Günlük fiyat değişimi: -0.4407% (17.7)
Haftalık fiyat değişimi: +5.47% (16.7088)
Aylık fiyat değişimi: -6.71% (18.89)
3 ayda fiyat değişimi: -9.68% (19.51)
Altı ayda fiyat değişimi: -14.52% (20.615)
Yıllık fiyat değişimi: -38.17% (28.5)
3 yılda fiyat değişimi: -38.77% (28.78)
Yılbaşından bu yana fiyat değişimi: -11.54% (19.92)

Hafife alma

İsim Anlam Seviye
P/S 211.58 1
P/BV 1.24 9
P/E 0 0
EV/EBITDA -3.8 0
Toplam: 3.63

Yeterlik

İsim Anlam Seviye
ROA, % -9.47 0
ROE, % -14.16 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0.0657

Görev

İsim Anlam Seviye
Debt/EBITDA -0.1806 10
Toplam: 9.6

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % -61.72 0
karlılık Ebitda, % -87.75 0
karlılık EPS, % -101.65 0
Toplam: 0

Kurumlar Hacim Paylaşmak, %
Pentwater Capital Management LP 10244 0.04
Tower Research Capital LLC (TRC) 43 0
UBS Group AG 20 0

ETFPaylaşmak, %Yıllık karlılık, %Temettüler, %
Amplify BlueStar Israel Technology ETF 0.30643 20.42 0.47569
Invesco Global Listed Private Equity ETF 0.29338 29.43 3.4983
Dimensional International Small Cap ETF 0.02653 5.69 3.34747
SPDR S&P International Small Cap ETF 0.0233 8.94 3.10348
Schwab International Small-Cap Equity ETF 0.0133 10.07 3.20638
SPDR Portfolio Europe ETF 0.00347 8.94 3.66537
Dimensional International Core Equity 2 ETF 0.00136 6.52 3.69996
Avantis International Equity ETF 0.00099 6.46 3.80856
Dimensional International Core Equity Market ETF 0.00032 13.09 3.48343
Vanguard FTSE All-World ex-US Small-Cap ETF 0 9.39 3.09932
Vanguard ESG International Stock ETF 0 6.39 3.07501
0.0611.393.13



Süpervizör İş unvanı Ödeme Doğum yılı
Ms. Daphne Zohar Founder, Senior Advisor & Board Observer 3.99M 1971 (54 yıl)
Dr. Bharatt M. Chowrira J.D., Ph.D. CEO & Executive Director 2.19M 1965 (60 yıllar)
Dr. David R. Elmaleh Ph.D. Co-Founder & Senior Advisor N/A 1948 (77 yıllar)
Ms. Allison Mead Talbot Head of Communications & Investor Relations N/A
Mr. Spencer Ball Senior Vice President of Human Resources N/A
Dr. Eric Elenko Ph.D. Co-Founder & President N/A 1973 (52 yıl)
Mr. Eric Green M.B.A. Chief Operating Officer N/A
Mr. Charles Sherwood III, J.D., Ph.D. General Counsel & Company Secretary N/A
Dr. Robert S. Langer Jr., Ph.D., ScD Co-Founder & Non-Executive Director 1949 (76 yıllar)
Mr. Michael Inbar CPA, M.B.A. Senior Vice President of Finance

Adres: United States, Boston. MA, 6 Tide Street - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.puretechhealth.com